Loading...

Loading...

Adjust height of sidebar

KMap

People

Adjust height of sidebar

KMap

Profile

Picture of Francois Chu

Francois Chu

Regulatory Coordinator I

Cancer Center Division

Collaboration(6)

Michele Chu-Pilli
Muhammad Husnain
Ravitharan Krishnadasan
Brianna Denton
Sharad Khurana

Page 1 of 2

Grants(4)

A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tai-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pom
Active·2023·$0 / $546.3K·
External
clinical trials, immunotherapy, multiple myeloma, combination therapy, drug development
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Active·2023·$0 / $464.7K·
External
cell therapy, cancer treatment, crispr, lymphoma, clinical trial
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritnib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (R/r Amil) With FMS-like Tyrosine Mutation (FLT3 mu
Active·2023·$0 / $116.3K·
External
acute myeloid leukemia, mutation, combination therapy, treatment
A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia
Active·2022·$0 / $2.4M·
External
stem cell transplantation, acute myeloid leukemia, venetoclax, azacitidine, efficacy and safety